Skip to main content

Search

As always, Janssen remains committed to healthcare professionals and patients, as well as to our employees and communities
As always, Janssen remains committed to healthcare professionals and patients, as well as to our employees and communities
COVID-19 Coronavirus Infections

Title

Covid19

 

 

Our innovative vaccine technology platform - AdVac® - offers hope for accelerated vaccine development. Janssen's AdVac® vectors are based on a specific type of adenovirus. This type of adenovirus has been genetically modified so that it can no longer multiply in humans and cannot cause disease. Because of this they are relatively harmless, and these viruses can be well used to induce desired immune responses in the human body. Want to know more about our AdVac® technology? Watch the video and read more here.

For COVID-19 related press questions,click here.

 

For COVID-19 vaccine information

Please use the contact details below:
Phone: +32 3 393 93 23
E-mail: [email protected] www.covid19vaccinejanssen.com

 

WHAT IS THE RESPONSE OF JANSSEN TO THE COVID-19 PANDEMIC?